tbuckley/cabot-search huggingface dataset:
Extracorporeal Photophoresis (ECP) For Chronic Graft Versus Host Disease (cGVHD): A Systemic Review and Meta-Analysis
Authors: Shahrukh K Hashmi, Mohsin Malik, Hassan Murad, Larry Prokop, William Hogan, Mrinal M Patnaik, Jeffrey L. Winters, Mark R. Litzow
Journal: Blood (2013)
A Role for Transforming Growth Factor-β1 in the Increased Pneumonitis in Murine Allogeneic Bone Marrow Transplant Recipients With Graft-Versus-Host Disease After Pulmonary Herpes Simplex Virus Type 1 Infection
Authors: Heiko Adler, Janice L. Beland, Wende Kozlow, Nadia C. Del-Pan, Lester Kobzik, Ilonna J. Rimm
Journal: Blood (1998)
Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes
Authors: Sameer A. Parikh, Tait D Shanafelt, Kari G. Rabe, Wei Ding, Timothy G. Call, Susan Schwager, Diane F. Jelinek, Neil E. Kay, Susan L Slager, Jose Leis
Journal: Blood (2013)
Intensified Conditioning Regimen Followed by Allogeneic Hct for Ph + All in First Cr
Authors: Hiroki Yokoyama, Shingo Yano, Takeshi Saito, Kazuhito Suzuki, Yutaro Kamiyama, Yoji Ogasawara, Katsuki Sugiyama, Yuichi Yahagi, Noriko Usui, Keisuke Aiba
Journal: Annals of Oncology (2014)
A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel
Authors: S. Goldman, B. Coiffier, A. Reiter, A. Younes, M. S. Cairo
Journal: Journal of Clinical Oncology (2009)

e17575 Background: We (MC) previously established a definition of laboratory (LTLS) and clinical TLS (CTLS) and associated grading system (Cairo et al, BJH. 2004). Additionally, we recently reported an evidence based review of guidelines for the P and T of TLS (Coiffier et al, J Clin Oncol. 2008). Rasburicase (R), a recombinant urate oxidase, results in a more rapid and total reduction of uric acid (UA) compared to allopurinol (A) in children at high-risk of TLS (Goldman/Cairo et al, Blood. 2001) and a rapid reduction in UA in adults at high-risk of TLS (Coiffier et al, J Clin Oncol. 2003). It still remains to be determined which patients at risk of developing TLS should receive R versus A as initial TLS prophylaxis. Methods: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol. 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD). Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement. HRD was assigned to patients with either B-ALL, ALL/AML ≥100K/mm 3 , BL/LL stage III/IV, and/or high LDH, DLBCL/PTCL/MCL/ATL with bulky and elevated LDH and patients with MRD with renal impairment/involvement. MRD consisted of ALL ≤100K/mm 3 , AML 25–100K/mm 3 , BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement. LRD consisted of ST (except bulky sensitive to cytotoxic therapy [MRD]), CML, MM, HL, other NHL and AML &lt;25K/mm 3 . Conclusions: This medical decision tree will facilitate the practice of management of the P and T of TLS and hopefully improve the quality of care in a cost effective manner. *all authors have equal authorship and contribution [Table: see text]
Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Authors: Koji Munakata, Mamoru Uemura, Shinji Tanaka, Kenji Kawai, Tomohiro Kitahara, Masaaki Miyo, Yoshihiro Kano, Shinpei Nishikawa, Takahito Fukusumi, Yusuke Takahashi, Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Masakazu Ikenaga, Takeshi Kato, Kohei Murata, John M. Carethers, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori
Journal: Clinical Cancer Research (2016)

One of the main reasons for cancer treatment resistance is the existence of cancer stem-like cells (CSCs). Here, we elucidated the relationship between low proteasome activity cells (LPACs) and CSCs.The human colorectal cancer cell lines HCT116, SW480, DLD1, and KM12SM were engineered to stably express a green fluorescent molecule fused to the degron of ornithine decarboxylase, resulting in an accumulation of the fluorescence in LPACs. LPACs were isolated by flow cytometry. Treatment resistance (radio- and chemotherapy) and the capacity of LPACs to act as CSCs were analyzed. Microarray analysis was performed to reveal genes related to treatment resistance. The prognostic impact of potent genes was examined in 190 patients with colorectal cancer.LPACs had a significantly increased capacity for radioresistance and chemoresistance (5-fluorouracil and oxaliplatin), significantly lower reactive oxygen species activity, and significantly increased sphere formation capacity compared with non-LPACs. The number of cells in the G0-G1 phase was significantly higher among LPACs. Subcutaneous injection of as few as 20 LPACs led to tumor formation in immunologically incompetent mice. Microarray analysis revealed that the expression of EP300-interacting inhibitor of differentiation 3 (EID3) was significantly increased in LPACs. In vitro assay revealed that EID3 positively controlled cell proliferation and treatment resistance. The high expression of EID3 was an adverse prognostic indicator in patients with colorectal cancer (P = 0.0400).LPACs have characteristic treatment resistance and act as CSCs in colorectal cancer. In addition, EID3 is one of the potential regulators of treatment resistance in colorectal cancer and may be a potential therapeutic target. Clin Cancer Res; 22(21); 5277-86. ©2016 AACR.
Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia
Authors: Rita Simone, Sonia Marsilio, Piers E.M. Patten, Gerardo Ferrer, Shih-Shih Chen, Xiao J. Yan, Stefano Vergani, Andrea Nicola Mazzarello, Jacqueline C. Barrientos, Steven L. Allen, Jonathan E. Kolitz, Kanti R. Rai, Nicholas Chiorazzi
Journal: Blood (2013)
Differential Induction of Apoptosis by Fludarabine Monophosphate in Leukemic B and Normal T Cells in Chronic Lymphocytic Leukemia
Authors: Ugo Consoli, Iman El-Tounsi, Alex Sandoval, Virginia Snell, Hans-Dieter Kleine, Wendy Brown, Johnnie R. Robinson, Francesco DiRaimondo, William Plunkett, Michael Andreeff
Journal: Blood (1998)
NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.
Authors: Louis Fehrenbacher, Jong-Hyeon Jeong, Priya Rastogi, Charles E. Geyer, Soonmyung Paik, Patricia A. Ganz, Stephanie R. Land, Joseph P. Costantino, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark
Journal: Journal of Clinical Oncology (2013)

TPS1139 Background: Adjuvant trastuzumab trials in HER2+ breast cancer (BC) demonstrated a large reduction in recurrence and death. Central testing showed HER2 non-amplified participants derived similar benefit. Among HER2-amplified patients (pts), multiple studies showed no effect on benefit by degree of amplification. Blinded internal and external review confirmed the non-amplified nature of the HER2 normal group. Based on these findings, NSABP B-47, sponsored by the NCI, was activated January 2011 and is actively accruing. The study is NCI central IRB approved, open via the CTSU, and endorsed by SWOG, ECOG, and RTOG. Methods: Study: Chemotherapy treatment is by physician choice: The non-anthracycline regimen is TC (docetaxel 75 mg/m2, cyclophosphamide (C) 600 mg/m2) IV q 3 wks for 6 cycles; the anthracycline regimen is AC → WP (doxorubicin 60 mg/m2 and C 600 mg/m2 IV either q 3 wks or q 2 wks [investigator discretion] for 4 cycles → paclitaxel 80 mg/m2 IV wkly for 12 doses). Pts are randomly assigned to chemotherapy with or without trastuzumab for 1 year. Pts receive adjuvant radiation therapy and endocrine therapy, as clinically indicated. Detailed menstrual history, concurrent medications, weight changes, and biomarkers (estrogen, stress, inflammation), are being collected. Eligibility: Eligibility includes: node positive or high risk node negative BC pts; HER2 IHC 1+ or 2+ scores, but non amplified by FISH; normal cardiac, renal, and liver function. Detailed eligibility will be provided. Statistical Design: The primary aim is to determine whether the addition of trastuzumab to chemotherapy improves invasive disease-free survival (IDFS). 3,260 pts will be enrolled to provide statistical power of 0.9 to detect a 33% reduction in the hazard rate of IDFS using a one-sided alpha level of 0.025. Progress: Protocol was activated in January 2011. First pt was entered in February 2011. As of January 23, 2013, 1,416 of 3,260 (43.4 %) pts have been enrolled. Updated information on enrollment and study background will be provided. Support: NCI U10-12027, -37377, 69651, 69974, and Genentech, Inc. Clinical trial information: NCT01275677.
A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC)
Authors: T. Buanes, J. Maurel, W. Liauw, M. Hebbar, J. Nemunaitis
Journal: Journal of Clinical Oncology (2009)

4601 Background: A phase I/II study with GV1001, a telomerase peptide vaccine, showed a median overall survival (OS) of 8.6 months in non-resectable PC (Bernhardt SL et al, Br J Cancer. 2006;95:1474–1482). This phase III trial was conducted to determine the impact on overall survival of G monotherapy vs. GV1001 in sequential combination with G in unresectable and metastatic PC. Methods: Eligible patients (pts) had chemotherapy-naive, advanced PC and ECOG performance status 0–1. Pts were randomized 1:1 to receive arm A: G (1,000 mg/m 2 30 min i.v.) weekly for 7 weeks (w), 1w off and then 3w during 4-weekly cycles, or arm B: GV1001 0.56 mg s.c. plus GM-CSF as immune adjuvant on days 1, 3, 5, 8, 15, 22, 36, then every 4 weeks. Patients who progressed clinically or radiologically during GV1001 continued on GV1001 and concomitant gemcitabine. CT scans were performed every 8 weeks. The primary end-point was OS. A sample size of 520 patients allowed the detection of a hazard ratio (HR) of 0.73 (B/A), with 2α = 0.05 and 90% power. Results: Between June 2006 and May 2008, 365 pts were enrolled (A / B; 182 / 183). The study was stopped prematurely due to a preliminary analysis with 178 events showing no survival benefit of GV1001. Pts were well balanced for baseline characteristics: male 59.3% / 62.8%; median age 61y / 61y; ECOG PS 0 34.3% / 36.7%; locally advanced 22.4% / 20.7%. As of August 2008, 238 pts (A / B : 114 / 124) had died. Median OS was 7.3 / 5.9 months (HR 0.8; 95% CI 0.6–1.0). Median progression-free survival (PFS) was 3.7 / 1.9 months (HR 0.5; 95%CI 0.4–0.7). Grade 3–4 AEs: gastrointestinal 6% / 8%, infection 5% / 5%, vascular disorders 2% / 3%, neutropenia 6% / 3%. Conclusions: GV1001 did not show efficacy in sequential combination with G in advanced PC. The advantage of G monotherapy over the sequential combination may be due to the delayed treatment with G in arm B. [Table: see text]
Short-Term Line of Normal Baboon Mammary Epithelial Cells2
Authors: Elsie Joe Rie, Ivo P. Rie, Gertrude Case Buehring
Journal: JNCI Journal of the National Cancer Institute (1976)

Cells from the breast fluids of 27 baboons (Papio anubis), 4 stump-tailed macaques (Macaca arctoides), and 5 rhesus macaques (M. mulatta) were grown in primary culture. A short-term mammary epithelial cell line (7 passages) was derived from cells of the breast fluids of 1 baboon. These cells were characterized as normal, epithelial, and baboon, by karyology, growth in both soft agar and methyl cellulose, and morphology by light and electron microscopy. Papanicolaou smears of breast fluid and mammography of the baboon revealed no abnormalities. The cells showed no evidence of tumor virus production.
Cerebellar Dysgenesis in Rats by Diaplacental Effects of 7,12-Dimethylbenz [ a ]anthracene 2
Authors: J. A. Kellen, A. Kolin, A. L. Fletch
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Cerebellar Dysgenesis in Rats by Diaplacental Effects of 7,12-Dimethylbenz [a]anthracene Get access J. A. Kellen, J. A. Kellen Search for other works by this author on: Oxford Academic PubMed Google Scholar A. Kolin, A. Kolin Search for other works by this author on: Oxford Academic PubMed Google Scholar A. L. Fletch A. L. Fletch Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 5, May 1976, Pages 1063–1067, https://doi.org/10.1093/jnci/56.5.1063 Published: 01 May 1976 Article history Received: 22 August 1975 Accepted: 11 November 1975 Published: 01 May 1976
Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model
Authors: Jashodeep Datta, Matthew T McMillan, Eric K Shang, Ronac Mamtani, Russell S Lewis, Rachel R Kelz, Ursina Teitelbaum, John P Plastaras, Jeffrey A Drebin, Douglas L Fraker, Giorgos C Karakousis, Robert E Roses
Journal: Journal of the National Comprehensive Cancer Network (2015)

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer recommend adjuvant chemotherapy with or without radiotherapy following after resection of gastric adenocarcinoma (GA) for patients who have not received neoadjuvant therapy. Despite frequent noncompliance with NCCN Guidelines nationally, risk factors underlying adjuvant therapy omission (ATom) have not been well characterized. We developed an internally validated preoperative instrument stratifying patients by incremental risk of ATom. The National Cancer Data Base was queried for patients with stage IB-III GA undergoing gastrectomy; those receiving neoadjuvant therapy were excluded. Multivariable models identified factors associated with ATom between 2006 and 2011. Internal validation was performed using bootstrap analysis; model discrimination and calibration were assessed using k-fold cross-validation and Hosmer-Lemeshow procedures, respectively. Using weighted β-coefficients, a simplified Omission Risk Score (ORS) was created to stratify ATom risk. The impact of ATom on overall survival (OS) was examined in ORS risk-stratified cohorts. In 4,728 patients (median age, 70 years; 64.8% male), 53.7% had ATom. The bootstrap-validated model identified advancing age, comorbidity, underinsured/uninsured status, proximal tumor location, and clinical T1/2 and N0 tumors as independent ATom predictors, demonstrating good discrimination. The simplified ORS, stratifying patients into low-, moderate-, and high-risk categories, predicted incremental risk of ATom (30% vs 53% vs 80%, respectively) and progressive delay to adjuvant therapy initiation (median time, 51 vs 55 vs 61 days, respectively). Patients at moderate/high-risk of ATom demonstrated worsening risk-adjusted mortality compared with low-risk patients (median OS, 26.4 vs 29.2 months). This ORS may aid in rational selection of multimodality treatment sequence in GA.
David Oliver: Nurse staffing levels are still not safe
Authors: David Oliver
Journal: BMJ (2016)

Setting out his vision to make the NHS “the safest in the world,” Jeremy Hunt has discussed the need for a less bureaucratic, more people centred system using data.1 But endless bureaucratic flip-flopping and political meddling over safe nurse staffing levels illustrate the emptiness of his rhetoric.

In the final 2013 report of his public inquiry into Mid Staffordshire Hospital,2 Robert Francis specifically recommended that “minimum safe staffing and skill-mix levels should be drawn up by the National Institute for Clinical Excellence [NICE] and policed by the Care Quality Commission [CQC].” …
Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC).
Authors: H. Beltran, S. Vallabhajosula, W. K. Kelly, Y. E. Whang, J. Osborne, K. Petrillo, S. J. Goldsmith, N. H. Bander, D. M. Nanus, S. T. Tagawa
Journal: Journal of Clinical Oncology (2010)

TPS247 Background: Nearly all prostate cancers express prostate specific membrane antigen (PSMA), with limited expression in other organs, making it an ideal therapeutic target. Monoclonal antibody J591 binds the extracellular domain of cells expressing PSMA with optimal affinity and is effectively internalized, with excellent targeting of metastatic sites when radiolabeled (Liu Clin Cancer Res 1997 & 1998, Milowsky JCO 2004, Bander JCO 2005). 177Lu is a radionuclide with gamma and short-range beta emission. A phase II trial of single-dose 177Lu-J591 radioimmunotherapy (RIT) in pts with metCRPC demonstrated efficacy with acceptable toxicity and an apparent dose-response relationship (Tagawa et al, ASCO 2008). It appears that dose-fractionation of 177Lu-J591 allows higher cumulative doses with less myelosuppression (Tagawa et al, submitted ASCO 2010). Docetaxel, which is standard chemotherapy for metCRPC, is a known radiosensitizer. We hypothesize that this combination will have superior clinical efficacy compared to either agent alone. The objective is to determine toxicity profile and maximal tolerated dose (MTD) of 177Lu-J591 plus docetaxel prior to the initiation of a phase II clinical trial. Methods: This is a multi-institutional phase I trial for men with progressive metCRPC that are docetaxel naive or have demonstrated prior docetaxel sensitivity. Docetaxel 75 mg/m2 is given every 3 weeks with prednisone 10 mg daily. Cohorts of 3-6 men receive escalated doses of fractionated 177Lu-J591 (20 mCi/m2 × 2, escalated in 5 mCi/m2 increments, to maximum of 45 mCi/m2 × 2). The initial dose of 177Lu-J591 is administered 2-3 days prior to cycle 3 of docetaxel to take advantage of initial chemotherapy debulking and to optimize radiosensitization (DeNardo Cancer 1997). Cycle 4 of docetaxel is administered upon adequate hematologic recovery. The primary endpoints are determination of MTD and toxicity profile. Secondary endpoints include response rate and survival. Exploratory objectives include the analysis of PSMA expression in circulating tumor cells and PSMA-based nuclear scans as biomarkers of response and/or toxicity with anti-PSMA-based RIT. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis
Vertebroplastia in patients with tumour injury of the vertebral body; therapeutic effect and short term complications
Authors: M. Marmol, J. Pomes, M. Muñoz, J. Macho, J. Blasco, A. Combalia, B. Farrus, E. Verger, X. Tomàs, P. Gascon
Journal: Journal of Clinical Oncology (2004)

8263 Background: Metastatic involvement of vertebral columnae affects performance status (PS) of cancer patients (pts) and compromise the efficacy of treatment. Radiotherapy and surgical management are therapeutical options to relieve tumour pain. (VP) can also be an effective modality to treat injured vertebrae. Our objectives were to analyse the clinical benefit of VP: in avoiding the interruption or delay of the chemotherapy treatment and to obtain pain relief without complications. Methods: From April 02 to November 03, a total of 26 VP were performed to 15 pts (7 males and 8 females) with vertebral body lesions. Median age: 58±17 years (22–76). Patients had: breast cancer (6), different solid tumors (7) and, hematologic malignancies (2). Pain was evaluated by means of a visual analogical pain scale (EVA), before the VP, as well at 24 hours, a week and a month after. The incidence of new fractures was also registered. Results: An average of 0.7 ± 1.7 (1–3) vertebrae/pt was performed. A new VP was done in two pts for a new lesion in another level. The basal EVA was of 8,1±1,3 (3–10) and, it decreased in the controls made at 24 hours, 1 week and one month. The EVA values averaged 1,1±1,3 (0–3), 0,2±0,4 (0–4), 1,7± 3,0 (0–9) (p<0.01) respectively. Seven pts (46%) were able to start or follow chemotherapy treatment in the next 24 hours after procedure. The cement leaks (CL) were characterized as anterior (3), posterior or back venous leak (6) and, cord channel leak (2). There was a complication in the form of one case of pulmonary embolism. A prospective study is planned in our Institution to include a larger number of patients and, to evaluate risks, benefits and quality of life. Conclusions: VP is an effective procedure for treating pain in patients with vertebral body tumour injury and, it appears to have an excellent safety profile. No significant financial relationships to disclose.
The Extent of Vitamin K Deficiency in Patients with Cholestatic Jaundice: A Preliminary Communication
Authors: D P O'Brien, M J Shearer, R P Waldron, P G Horgan, H F Given
Journal: Journal of the Royal Society of Medicine (1994)

Eleven patients with cholestatic jaundice had measurements of plasma vitamin K 1 performed. Seven of these 11 (64%) had subnormal levels. The prothrombin time (PT) was prolonged in three of 15 patients with cholestasis (20%), the patient with the longest PT had the lowest vitamin K 1 level. A single intramuscular (im) dose of 10 mg vitamin K 1 lowered the PT in 9/15 patients (includes correcting the three prolonged PTs). The initial mean plasma vitamin K 1 level rose 24 h later, to a mean plasma level which was 33 times the upper limit of the normal physiological range. These preliminary results suggest that a majority of patients presenting with cholestatic jaundice have low tissue reserves of vitamin K 1 , and that guidelines for vitamin K 1 therapy in patients with cholestatic jaundice should be revised.
Becoming a better medical leader
Authors: Peter Spurgeon, Bob Klaber, Matt Green
Journal: BMJ (2012)

<b>Peter Spurgeon</b> and <b>Bob Klaber</b>, authors of <i>Medical Leadership: A Practical Guide for Trainees and Trainers</i>, together with <b>Matt Green</b> of the BPP University College’s School of Health, explore the relevance of the Medical Leadership Competency Framework in modern day medicine and how it can be used as a guiding framework at every stage of a doctor’s career
Sixty seconds on . . . measuring blood pressure
Authors: Nigel Hawkes
Journal: BMJ (2016)

You may think you’re doing it right, but are you taking measurements from both arms? 

The recommendation came in NICE guidance CG34, issued in 2006. A 2007 study by Carl Heneghan and colleagues of Oxford’s Centre for Evidence-Based Medicine found that although 77% of GPs were aware of the guidance, only 30% agreed with it and even fewer, 13%, …
Visitors are using US website to search for high prescribing doctors
Authors: Michael McCarthy
Journal: BMJ (2016)

The US investigative journalism website ProPublica has found that many visitors to its online database that provides information on US physicians’ prescribing practices seem to be searching for doctors who freely prescribe opioids and other widely misused drugs.

In an article posted on 12 May the website’s editor in chief, Stephen Engelberg, said that its staff had created the searchable database, called Prescriber Checkup (https://projects.propublica.org/checkup), to provide …
Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis
Authors: Sajitha Sachchithanantham, Shameem Mahmood, Rabya Sayed, Ketna Patel, Marianna Fontana, Thirusha Lane, Lisa Rannigan, Darren Foard, Carol Whelan, Helen Lachmann, Julian D Gillmore, Philip N Hawkins, Ashutosh Wechalekar
Journal: Blood (2013)